Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06497127 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Mixed Dyslipidemia
A Phase 2 study of Mixed Dyslipidemia, sponsored by Shanghai Argo Biopharmaceutical Co..
- Active
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
- 14
- Study locations
NCT06497127 is a Phase 2 study of Mixed Dyslipidemia that is active but no longer recruiting, run by Shanghai Argo Biopharmaceutical Co.. The registered enrollment target is 145 participants, below the 691-participant average among 3 other Mixed Dyslipidemia trials with a reported enrollment target (79% lower). The trial reports 14 study locations across 8 states.
The verdict
NCT06497127, a Phase 2 study of Mixed Dyslipidemia, is active but no longer recruiting, sponsored by Shanghai Argo Biopharmaceutical Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Phase 2 in Patients With Mixed Dyslipidemia
Conditions Studied
Interventions
- DRUG BW-00112
Study Locations (14)
Florida
- Excel Medical Clinical Trials, LLC, dba Flourish Research - Boca Raton
- East Coast Institute for Research, LLC - Jacksonville
- Clinical Site Partners Leesburg, LLC dba Flourish Research - Leesburg
- Suncoast Research Group, LLC DBA Flourish Research - Miami
- Clinical Site Partners, LLC DBA Flourish Research - Miami
Alabama
- Alliance for Multispecialty Research, LLC - Daphne
- Alliance for Multispecialty Research, LLC - Mobile
Illinois
- Alliance for Multispecialty Research, LLC - Oak Brook
- Alliance for Multispecialty Research, LLC - Park Ridge
Georgia
- East Coast Institute for Research LLC - Canton
Kansas
- Alliance for Multispecialty Research, LLC - Newton
New York
- Icahn School of Medicine at Mount Sinai - New York
Oklahoma
- Alliance for Multispecialty Research, LLC - Norman
Texas
- Clinical Trials of Texas, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2024-02-28 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06497127
The ClinicalTrials.gov registry entry for NCT06497127 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 691-participant average among 3 other Mixed Dyslipidemia trials with a reported enrollment target (79% lower). The listed sponsor is Shanghai Argo Biopharmaceutical Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mixed Dyslipidemia appearing as the primary indexed condition, and to 1 intervention - of which BW-00112 is the first listed.
NCT06497127 reports 14 study locations spanning 8 distinct geographic areas - top geographies include Florida, Alabama, Illinois.
Frequently Asked Questions
What is clinical trial NCT06497127 about?
NCT06497127 is a clinical study titled "A Study in Patients With Mixed Dyslipidemia". A Phase 2 in Patients With Mixed Dyslipidemia
What is the current status of trial NCT06497127?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2024-02-28. Estimated completion is 2028-03-30.
What conditions does trial NCT06497127 study?
This clinical trial studies the following conditions: Mixed Dyslipidemia.
What interventions are being tested in trial NCT06497127?
The interventions under investigation include: BW-00112 (DRUG).
Who is sponsoring clinical trial NCT06497127?
This trial is sponsored by Shanghai Argo Biopharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06497127 being conducted?
This trial has 14 study locations across Alabama, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mixed Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
COMPLETED · Phase 2
-
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
COMPLETED · Phase 3
-
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.